The Fabry disease treatment market is projected to grow from USD 2.42 billion in 2024 to USD 4.61 billion by 2032, with a CAGR of 8.47%. This growth is driven by increased disease awareness, early diagnosis, R&D funding, and advancements in therapies like enzyme replacement therapy (ERT), chaperone therapy, and substrate reduction therapy (SRT). Regulatory support, government incentives, and technological innovations in genomic diagnostics are also key factors. Challenges include high treatment costs and access disparities in low-income regions.

The global Fabry disease treatment market reached USD 1,876.7 million in 2022 and is projected to grow to USD 3,287.2 million by 2031, with a CAGR of 7.4% (2024-2031). The report highlights key players like Sanofi, Takeda, and Amgen, recent FDA approvals for therapies like Elfabrio and ST-920, and market segments by drug type, treatment method, and distribution channel.

The Fabry disease market is projected to grow significantly from 2020 to 2034, driven by rising prevalence, improved diagnostics, and emerging therapies. Key players like Sanofi, Sangamo Therapeutics, and Idorsia Pharmaceuticals are advancing treatments, including gene therapies and oral chaperone drugs. Challenges include pediatric treatment gaps, high costs, and limited access in low-resource regions. The market is segmented into 7MM (United States, EU4, UK, Japan) with the U.S. accounting for 52% of the 2024 market size.

Bristol Myers Squibb is closing a gene-therapy manufacturing facility in Libertyville, Illinois, and laying off 133 employees as part of a $2 billion cost-cutting effort to consolidate production in Devens, Massachusetts. The facility, previously owned by Novartis and later acquired by Bristol Myers Squibb, is the second time the site has been closed due to consolidation strategies.

A research report by Exactitude Consultancy, Ltd. outlines projected market growth for Fabry Disease, estimating a CAGR of 8.6% from 2025 to 2034, with market size rising from $1.9 billion in 2024 to $4.5 billion by 2034. The report analyzes production processes, market segments, and growth drivers, while excluding regions accelerating marketization.